MBL Wealth LLC Purchases New Stake in Medpace Holdings, Inc. $MEDP

MBL Wealth LLC bought a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 847 shares of the company’s stock, valued at approximately $529,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Root Financial Partners LLC bought a new stake in Medpace in the 3rd quarter valued at $198,000. Cantor Fitzgerald Investment Advisors L.P. acquired a new stake in Medpace in the 3rd quarter worth about $1,791,000. Crossmark Global Holdings Inc. raised its position in shares of Medpace by 3.6% in the third quarter. Crossmark Global Holdings Inc. now owns 6,312 shares of the company’s stock valued at $3,940,000 after buying an additional 218 shares in the last quarter. Nisa Investment Advisors LLC raised its holdings in Medpace by 14.3% in the 3rd quarter. Nisa Investment Advisors LLC now owns 1,044 shares of the company’s stock valued at $652,000 after acquiring an additional 131 shares in the last quarter. Finally, Diversify Advisory Services LLC lifted its position in Medpace by 6.9% during the third quarter. Diversify Advisory Services LLC now owns 5,360 shares of the company’s stock worth $3,369,000 after purchasing an additional 344 shares during the period. Institutional investors own 77.98% of the company’s stock.

Key Stories Impacting Medpace

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: New $1 billion buyback: Medpace authorized a $1 billion repurchase program, replacing its previous authorization. The plan signals management’s confidence in cash generation and could support earnings per share by reducing the share count. Medpace Announces $1 Billion Stock Buyback Program
• Positive Sentiment: Raised 2026 outlook: The company forecast adjusted EPS of $17.97–$18.32, above the $17.68 analyst consensus, while revenue guidance of $2.8–$2.9 billion is broadly consistent with expectations. Medpace 2026 Guidance and Buyback
• Positive Sentiment: Q3 earnings beat: Medpace reported earnings of $4.84 per share versus the $4.45 consensus estimate, with revenue of approximately $716 million and year-over-year revenue growth of 8.5%. Margin expansion helped drive the earnings outperformance. Medpace Q3 Earnings Beat
• Positive Sentiment: Demand remains healthy: Net new business awards reached $873 million in the third quarter, and ending backlog increased 5.6% year over year to $3.2 billion, supporting future revenue visibility. Medpace Long-Term Investor Takeaways
• Neutral Sentiment: Analyst targets moved higher but ratings remain cautious: TD Cowen raised its target to $673 from $492 and kept a “hold” rating, while Deutsche Bank increased its target to $650 and also maintained “hold.” These revisions acknowledge the improved outlook but imply limited upside at recent trading levels. TD Cowen Medpace Rating
• Negative Sentiment: Valuation remains a concern: Commentary following the results questioned whether MEDP is already pricing in much of its growth, with some analysis describing the shares as materially overvalued despite the earnings beat. This may explain the initial post-earnings hesitation.

Insider Buying and Selling

In other Medpace news, CEO August Troendle sold 21,966 shares of the business’s stock in a transaction on Wednesday, September 30th. The stock was sold at an average price of $625.47, for a total value of $13,739,074.02. Following the transaction, the chief executive officer owned 338,225 shares of the company’s stock, valued at approximately $211,549,590.75. The trade was a 6.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 336,140 shares of company stock worth $208,008,328 in the last 90 days. Company insiders own 20.50% of the company’s stock.

Wall Street Analysts Forecast Growth

MEDP has been the subject of several recent analyst reports. Robert W. Baird set a $699.00 target price on Medpace in a research note on Friday. Mizuho set a $730.00 target price on shares of Medpace in a research report on Friday. UBS Group upped their price target on Medpace from $673.00 to $700.00 and gave the company a “neutral” rating in a research report on Friday. TD Cowen upped their price objective on shares of Medpace from $492.00 to $673.00 and gave the company a “hold” rating in a research note on Friday. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $535.00 target price on shares of Medpace in a research note on Thursday, July 23rd. Three research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $642.91.

Medpace Stock Up 2.3%

Shares of Medpace stock opened at $669.20 on Friday. The company has a market cap of $18.68 billion, a PE ratio of 37.10, a price-to-earnings-growth ratio of 2.97 and a beta of 1.18. The business has a 50 day moving average price of $611.66 and a 200-day moving average price of $537.67. Medpace Holdings, Inc. has a 52 week low of $373.00 and a 52 week high of $684.52.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Wednesday, October 21st. The company reported $4.84 earnings per share for the quarter, beating the consensus estimate of $4.44 by $0.40. Medpace had a return on equity of 99.76% and a net margin of 18.24%. The business had revenue of $716.00 million for the quarter, compared to analysts’ expectations of $714.47 million. During the same period last year, the business earned $3.86 EPS. The business’s revenue was up 8.5% on a year-over-year basis. As a group, research analysts anticipate that Medpace Holdings, Inc. will post 18.06 EPS for the current year.

Medpace Profile

Medpace Holdings, Inc is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the development process, from early-stage planning and regulatory submissions through clinical trial execution, data management, analysis and reporting.

Medpace’s services include Phase I through Phase IV clinical research, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.